Nerlynx (Neratinib)

Neratinib, the active ingredient in Nerlynx, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for extended adjuvant treatment of HER2‑positive early‑stage breast cancer in patients who have completed trastuzumab‑based therapy.

GNH USA supplies Nerlynx as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Neratinib acts on the HER2 signaling pathway and is used in HER2‑positive breast cancer management.

- Extended adjuvant treatment of HER2‑positive early‑stage breast cancer following trastuzumab therapy: reduces risk of disease recurrence. - HER2‑positive early‑stage breast cancer after surgery: provides continued HER2 inhibition to improve disease‑free survival. - HER2‑positive breast cancer in patients who have completed adjuvant trastuzumab: serves as maintenance therapy to sustain HER2 blockade.

Neratinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often mild to moderate, may require antidiarrheal therapy. - Nausea and vomiting: can be managed with antiemetics. - Abdominal pain: intermittent discomfort. - Fatigue: generalized tiredness. - Rash: skin irritation or erythema. - Stomatitis: inflammation of the mouth lining.

Serious or Rare Side Effects: - Severe diarrhea leading to dehydration: may require hospitalization. - Hepatotoxicity: elevated liver enzymes or liver injury. - Interstitial lung disease: respiratory symptoms requiring immediate attention. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Neutropenia: low white‑blood‑cell count increasing infection risk.

Patients should be monitored closely for safety concerns while receiving Neratinib.

- Liver function monitoring: assess transaminases before and during therapy. - Cardiac assessment: evaluate baseline and periodic cardiac function. - Diarrhea management: initiate prophylactic antidiarrheal agents and educate on hydration. - Avoid use in severe hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: discuss risks with prescriber; drug may be contraindicated. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Neratinib may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase neratinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce neratinib effectiveness. - Antacids that markedly raise gastric pH: may affect absorption.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., certain immunosuppressants): monitor plasma levels. - Anticoagulants such as warfarin: watch for changes in INR. - Proton pump inhibitors: may modestly decrease neratinib exposure. - Antidiarrheal agents (e.g., loperamide): adjust dose if needed. - Oral contraceptives: assess contraceptive efficacy, consider additional methods.